

# CITATION REPORT

List of articles citing

## Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies

DOI: 10.1634/theoncologist.2017-0348  
Oncologist, 2018, 23, 403-409.

**Source:** <https://exaly.com/paper-pdf/69192911/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	Docetaxel/doxorubicin. <i>Reactions Weekly</i> , <b>2018</b> , 1702, 101-101	0	0
7	Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim. <i>BioDrugs</i> , <b>2019</b> , 33, 635-645	7.9	4
6	Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis. <i>BioDrugs</i> , <b>2019</b> , 33, 373-389	7.9	13
5	Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects. <i>Clinical Drug Investigation</i> , <b>2021</b> , 41, 29-42	3.2	1
4	Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 857-865	4	0
3	Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2021</b> , 27, 660-666	1.9	2
2	NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 12-22	7.3	44
1	BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated With High-Neutropenia Risk Chemotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> ,	7.3	0